Keywords: Amarin, Vascepa, Triglyceride levels, USA, FDA< GlaxoSmithKline, Lovaza, Possible sales of company

US FDA clears Amarin's Vascepa, a competitor for Lovaza

Article | 30 July 2012

Print This

The US Food and Drug Administration has approved biotech firm Amarin’s (Nasdaq: AMRN) Vascepa (icosapent ethyl) capsules (formerly ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in